Advent Access completes CE Mark submission for av-Guardian™ , 2018

20 Sep 2018

Advent Access is pleased to announce that our av-Guardian implant technology has completed regulatory submission and key audits for the CE Mark. The clinical trial results used in this submission had also been accepted to be presented at a renowned scientific conference later this year. This is an exciting milestone for us as it represents an important step towards commercialising the av-Guardian and unlocking the future of dialysis in novel or alternative care environments.


Read more


Share on Facebook
Share on Twitter
Please reload

Recent Posts
Please reload

Please reload

©2019 By Advent Access Pte. Ltd. All Rights Reserved.